Top

Published in:

01-04-2014 | Original Article

Mortalin is a prognostic factor of gastric cancer with normal p53 function

Authors: Koji Ando, Eiji Oki, Yan Zhao, Ayae Ikawa-Yoshida, Hiroyuki Kitao, Hiroshi Saeki, Yasue Kimura, Satoshi Ida, Masaru Morita, Tetsuya Kusumoto, Yoshihiko Maehara

Published in: Gastric Cancer | Issue 2/2014

Abstract

Background

Mortalin is a heat-non-inducible member of the heat shock protein 70 family. Mortalin binds to p53 and prevents p53 from entering the nucleus. To understand the significance of mortalin in gastric cancer, we investigated the expression of mortalin and p53.

Methods

Expression of mortalin and p53 was examined by immunohistochemical staining of 182 clinical samples of gastric cancer.

Results

Mortalin-positive and aberrant p53-positive tumors were found in 75.2 and 49.5 % of cases, respectively. Mortalin-positive tumors were deeper in invasion and had more lymph node and liver metastases compared with mortalin-negative tumors (P < 0.01, P < 0.05, respectively). Mortalin-positive tumors had worse prognosis compared with mortalin-negative tumors (P = 0.035). Moreover, in tumors with normal p53 function, mortalin-positive tumors had worse prognosis compared with mortalin-negative tumors (P = 0.017).

Conclusions

Mortalin has a great impact on gastric cancer with normal p53. Therefore, mortalin is a target molecule for treatment of gastric cancer, as well as a promising prognostic factor, especially in tumors with normal p53.

Wadhwa R, Kaul SC, Ikawa Y, Sugimoto Y. Identification of a novel member of mouse hsp70 family. Its association with cellular mortal phenotype. J Biol Chem. 1993;268:6615–21.PubMed

Kaul SC, Duncan E, Sugihara T, Reddel RR, Mitsui Y, Wadhwa R. Structurally and functionally distinct mouse hsp70 family members Mot-1 and Mot-2 proteins are encoded by two alleles. DNA Res. 2000;7:229–31.PubMedCrossRef

Kaul SC, Duncan EL, Englezou A, Takano S, Reddel RR, Mitsui Y, Wadhwa R. Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein. Oncogene. 1998;17:907–11.PubMedCrossRef

Liu Y, Liu W, Song XD, Zuo J. Effect of GRP75/mthsp70/PBP74/mortalin overexpression on intracellular ATP level, mitochondrial membrane potential and ROS accumulation following glucose deprivation in PC12 cells. Mol Cell Biochem. 2005;268:45–51.PubMedCrossRef

Merrick BA, Walker VR, He C, Patterson RM, Selkirk JK. Induction of novel Grp75 isoforms by 2-deoxyglucose in human and murine fibroblasts. Cancer Lett. 1997;119:185–90.PubMedCrossRef

Sadekova S, Lehnert S, Chow TY. Induction of PBP74/mortalin/Grp75, a member of the hsp70 family, by low doses of ionizing radiation: a possible role in induced radioresistance. Int J Radiat Biol. 1997;72:653–60.PubMedCrossRef

Mizukoshi E, Suzuki M, Loupatov A, Uruno T, Hayashi H, Misono T, Kaul SC, Wadhwa R, Imamura T. Fibroblast growth factor-1 interacts with the glucose-regulated protein GRP75/mortalin. Biochem J. 1999;343(Pt 2):461–6.PubMedCrossRefPubMedCentral

Takano S, Wadhwa R, Mitsui Y, Kaul SC. Identification and characterization of molecular interactions between glucose-regulated proteins (GRPs) mortalin/GRP75/peptide-binding protein 74 (PBP74) and GRP94. Biochem J. 2001;357:393–8.PubMedCrossRefPubMedCentral

Wadhwa R, Yaguchi T, Hasan MK, Taira K, Kaul SC. Mortalin–MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation. Biochem Biophys Res Commun. 2003;302:735–42.PubMedCrossRef

10.

Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR, Mitsui Y, Kaul SC. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem. 1998;273:29586–91.PubMedCrossRef

11.

Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR, Kaul SC. Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res. 2002;274:246–53.PubMedCrossRef

12.

Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddel RR, Kaul SC. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer. 2006;118:2973–80.PubMedCrossRef

13.

Wadhwa R, Takano S, Taira K, Kaul SC. Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells. J Gene Med. 2004;6:439–44.PubMedCrossRef

14.

Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol. 2005;205:74–81.PubMedCrossRef

15.

Aikou T, Hokita S, Natsugoe S. Japanese classification of gastric carcinoma (the 13th edition, June 1999): points to be revised. Nippon Rinsho. 2001;59(Suppl 4):159–65.PubMed

16.

Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res. 1994;54:3752–7.PubMed

17.

Kaserer K, Schmaus J, Bethge U, Migschitz B, Fasching S, Walch A, Herbst F, Teleky B, Wrba F. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J Pathol. 2000;190:450–6.PubMedCrossRef

18.

Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA. 1990;87:7555–9.PubMedCrossRefPubMedCentral

19.

Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H, Maehara Y. Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res. 2006;12:5112–7.PubMedCrossRef

20.

el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1992;1:45–9.PubMedCrossRef

21.

Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293–9.PubMedCrossRef

22.

Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683–94.PubMedCrossRef

23.

Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053–8.PubMedCrossRef

24.

Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–45.PubMedCrossRef

25.

Beroud C, Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum Mutat. 2003;21:176–81.PubMedCrossRef

26.

Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 1998;58:4023–37.PubMed

27.

Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92:434–44.PubMedPubMedCentral

28.

Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23:7518–28.PubMedCrossRef

29.

Kaul SC, Deocaris CC, Wadhwa R. Three faces of mortalin: a housekeeper, guardian and killer. Exp Gerontol. 2007;42:263–74.PubMedCrossRef

30.

Koya K, Li Y, Wang H, Ukai T, Tatsuta N, Kawakami M, Shishido T, Chen LB. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res. 1996;56:538–43.PubMed

31.

Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, Simpson R, Maruta H, Kaul SC. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res. 2000;60:6818–21.PubMed

32.

Propper DJ, Braybrooke JP, Taylor DJ, Lodi R, Styles P, Cramer JA, Collins WC, Levitt NC, Talbot DC, Ganesan TS, Harris AL. Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours. Ann Oncol. 1999;10:923–7.PubMedCrossRef

33.

Deocaris CC, Widodo N, Shrestha BG, Kaur K, Ohtaka M, Yamasaki K, Kaul SC, Wadhwa R. Mortalin sensitizes human cancer cells to MKT-077-induced senescence. Cancer Lett. 2007;252:259–69.PubMedCrossRef

Title: Mortalin is a prognostic factor of gastric cancer with normal p53 function
Authors: Koji Ando
Eiji Oki
Yan Zhao
Ayae Ikawa-Yoshida
Hiroyuki Kitao
Hiroshi Saeki
Yasue Kimura
Satoshi Ida
Masaru Morita
Tetsuya Kusumoto
Yoshihiko Maehara
Publication date: 01-04-2014
Publisher: Springer Japan
Published in: Gastric Cancer / Issue 2/2014
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI: https://doi.org/10.1007/s10120-013-0279-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Mortalin is a prognostic factor of gastric cancer with normal p53 function

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2014

Clinical application of ghrelin administration for gastric cancer patients undergoing gastrectomy

Optimal chemotherapy for advanced gastric cancer: is there a global consensus?

Genetic polymorphism of cytochrome P450 (CYP) 1A1, CYP1A2, and CYP2E1 genes modulate susceptibility to gastric cancer in patients with Helicobacter pylori infection

Endoscopic submucosal dissection for early gastric cancer in anastomosis site after distal gastrectomy

Aberrant expression of SOX9 is associated with gastrokine 1 inactivation in gastric cancers

Can we apply the same indication of endoscopic submucosal dissection for primary gastric cancer to remnant gastric cancer?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page